**Core Concept**
The patient presents with symptoms of community-acquired pneumonia (CAP), an infection of the lung parenchyma caused by various pathogens, most commonly Streptococcus pneumoniae. The treatment of CAP requires prompt initiation of antibiotics to target the causative organism and alleviate symptoms.

**Why the Correct Answer is Right**
The most appropriate treatment of CAP is empiric antibiotic therapy, targeting the most likely pathogens based on the patient's presentation and risk factors. In this case, the patient is a young adult, and the most likely causative organisms are Streptococcus pneumoniae and Haemophilus influenzae. The recommended empiric treatment for CAP is a beta-lactam antibiotic, such as ceftriaxone, in combination with a macrolide, such as azithromycin, or a fluoroquinolone, such as levofloxacin. This combination provides broad-spectrum coverage against the most common CAP pathogens.

**Why Each Wrong Option is Incorrect**
**Option A:** Vancomycin is a glycopeptide antibiotic that is typically reserved for patients with severe CAP or those at high risk of resistant organisms. It is not the first-line treatment for CAP in a young adult.
**Option B:** Linezolid is an oxazolidinone antibiotic that is typically used to treat resistant Gram-positive infections. It is not the first-line treatment for CAP.
**Option C:** Doxycycline is a tetracycline antibiotic that is not typically used as first-line treatment for CAP due to its limited coverage against common CAP pathogens.

**Clinical Pearl / High-Yield Fact**
In patients with CAP, it is essential to consider the patient's risk factors for resistant organisms, such as recent antibiotic use, healthcare exposure, or underlying medical conditions, to guide empiric antibiotic selection.

**Correct Answer:** C. Ceftriaxone, 1 g IV q 24 hours + Azithromycin, 500 mg IV q 24 hours.